Fecal Transplantation Against Recurrent Clostridium difficile Infection
Abstract Clostridium difficile is a spore-forming Gram-positive intestinal inhabitant of many asymptomatic and symptomatic individuals. In the past, it was thought to have a commensal relationship with us but recent research has cast doubt on this. C. difficile infection (CDI) is a major public health concern and is associated with a decrease in fecal microbial diversity. In addition, the disrupted gastroduodenal microbial ecosystem by first-line antibiotic therapy is a predisposing factor for bacterial overgrowth by C. difficile. Given its high prevalence and the increasing incidence of virulent C. difficile isolates worldwide, with concomitant increased mortality and morbidity, new interventions including fecal microbiota transplantation (FMT) are urgently needed. The main rationale for FMT is to rebalance the gut microbiota. Undoubtedly, FMT is safe and efficacious enough to recommend it to decision-makers in order to institute routine application in clinical practices..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
BioNanoScience - 8(2018), 3 vom: 09. Juli, Seite 941-943 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abadi, Amin Talebi Bezmin [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© Springer Science+Business Media, LLC, part of Springer Nature 2018 |
|---|
| doi: |
10.1007/s12668-018-0545-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR026924307 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR026924307 | ||
| 003 | DE-627 | ||
| 005 | 20230519081252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12668-018-0545-0 |2 doi | |
| 035 | |a (DE-627)SPR026924307 | ||
| 035 | |a (SPR)s12668-018-0545-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abadi, Amin Talebi Bezmin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fecal Transplantation Against Recurrent Clostridium difficile Infection |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media, LLC, part of Springer Nature 2018 | ||
| 520 | |a Abstract Clostridium difficile is a spore-forming Gram-positive intestinal inhabitant of many asymptomatic and symptomatic individuals. In the past, it was thought to have a commensal relationship with us but recent research has cast doubt on this. C. difficile infection (CDI) is a major public health concern and is associated with a decrease in fecal microbial diversity. In addition, the disrupted gastroduodenal microbial ecosystem by first-line antibiotic therapy is a predisposing factor for bacterial overgrowth by C. difficile. Given its high prevalence and the increasing incidence of virulent C. difficile isolates worldwide, with concomitant increased mortality and morbidity, new interventions including fecal microbiota transplantation (FMT) are urgently needed. The main rationale for FMT is to rebalance the gut microbiota. Undoubtedly, FMT is safe and efficacious enough to recommend it to decision-makers in order to institute routine application in clinical practices. | ||
| 650 | 4 | |a Fecal microbiota transplantation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Improved management |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Wren, Allison |4 aut | |
| 700 | 1 | |a Abdulkhakov, Sayar R. |4 aut | |
| 700 | 1 | |a Rizvanov, Albert A. |0 (orcid)0000-0002-9427-5739 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BioNanoScience |d New York, NY [u.a.] : Springer, 2011 |g 8(2018), 3 vom: 09. Juli, Seite 941-943 |w (DE-627)SPR026864177 |w (DE-600)2606470-4 |x 2191-1649 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2018 |g number:3 |g day:09 |g month:07 |g pages:941-943 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12668-018-0545-0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2018 |e 3 |b 09 |c 07 |h 941-943 | ||